20/20 Biolabs holders back equity plan, delay charter

20/20 Biolabs, Inc. (AIDX) reported the results of its August 18, 2026 annual stockholders meeting held via webcast.

Rhea-AI Filing Summary

20/20 Biolabs, Inc. (AIDX) reported the results of its August 18, 2026 annual stockholders meeting held via webcast. Stockholders of record on June 22, 2026, holding 12,251,198 common shares, were entitled to vote, and 4,256,837 shares were represented, constituting a quorum.

Six directors were elected, each receiving roughly 2.65–2.73 million votes for and about 156–176 thousand votes withheld, with 1,433,721 broker non-votes on each director. Stockholders ratified dbbmckennon as independent registered public accounting firm for 2026 with 4,105,584 votes for, 132,421 against, and 18,832 abstentions. They also approved the 2026 Equity Incentive Plan with 2,183,335 votes for, 573,931 against, 65,850 abstentions, and 1,433,721 broker non-votes, and approved the ability to adjourn the meeting if needed, by 3,037,106 votes for, 1,132,166 against, and 87,565 abstentions. A charter amendment proposal did not receive sufficient votes and the meeting was adjourned on that item to September 16, 2026.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares outstanding entitled to vote: 12,251,198 shares Shares represented at meeting: 4,256,837 shares Broker non-votes on director elections: 1,433,721 +3 more

6 metrics

Shares outstanding entitled to vote 12,251,198 shares Common stock outstanding and entitled to vote as of June 22, 2026

Shares represented at meeting 4,256,837 shares Shares present in person or by proxy at August 18, 2026 annual meeting

Broker non-votes on director elections 1,433,721 Broker non-votes recorded on each of the six director election proposals

Auditor ratification votes for 4,105,584 Votes in favor of ratifying dbbmckennon for fiscal year ending December 31, 2026

Equity Plan approval votes for 2,183,335 Votes in favor of the 2026 Equity Incentive Plan

Adjournment proposal votes for 3,037,106 Votes in favor of allowing adjournment to solicit additional proxies

Key Terms

broker non-votes, quorum, independent registered public accounting firm, Equity Incentive Plan, +1 more

5 terms

broker non-votes financial

"The votes regarding this proposal were as follows ... Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

quorum regulatory

"4,256,837 shares of common stock were represented...constituting a quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

independent registered public accounting firm financial

"ratified the appointment of dbbmckennon as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Equity Incentive Plan financial

"The Company’s stockholders approved the Company’s 2026 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

adjournment of the Annual Meeting regulatory

"approved the adjournment of the Annual Meeting to a later date if necessary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did 20/20 Biolabs, Inc. (AIDX) announce regarding its 2026 annual meeting?

20/20 Biolabs, Inc. announced final voting results from its August 18, 2026 annual meeting. Six directors were elected, the auditor was ratified, a 2026 Equity Incentive Plan was approved, and stockholders authorized potential adjournment to solicit additional proxies.

How many AIDX shares were eligible and present for the 2026 annual meeting vote?

As of June 22, 2026, 12,251,198 AIDX common shares were outstanding and entitled to vote. At the August 18, 2026 meeting, 4,256,837 shares were represented in person or by proxy, which the company states constituted a quorum.

Were all director nominees elected at 20/20 Biolabs’ 2026 annual meeting?

Yes. All six nominees to the 20/20 Biolabs board were elected. Each director received about 2.65–2.73 million votes for, between roughly 156,000 and 176,000 votes withheld, and there were 1,433,721 broker non-votes for each director election.

Did AIDX stockholders ratify the company’s independent auditor for 2026?

Yes. Stockholders ratified dbbmckennon as independent registered public accounting firm for the year ending December 31, 2026, with 4,105,584 votes for, 132,421 against, and 18,832 abstentions, indicating strong support for the appointment.

Was 20/20 Biolabs’ 2026 Equity Incentive Plan approved by AIDX stockholders?

Yes. The 2026 Equity Incentive Plan was approved with 2,183,335 votes for, 573,931 against, 65,850 abstentions, and 1,433,721 broker non-votes. This authorization allows grants of equity-based awards under the new plan structure going forward.

What happened to the charter amendment proposal at AIDX’s 2026 annual meeting?

The charter amendment proposal did not receive sufficient votes at the August 18, 2026 meeting. In line with a separate adjournment proposal, the company adjourned voting on this item until September 16, 2026 to solicit additional proxies.

What was decided about adjourning 20/20 Biolabs’ 2026 annual meeting if needed?

Stockholders approved the ability to adjourn the annual meeting to solicit more proxies if needed. The adjournment proposal received 3,037,106 votes for, 1,132,166 against, and 87,565 abstentions, enabling the later adjournment on the charter amendment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 09:19 AM EDT Accepted by SEC EDGAR 08/19/2026 - 09:19 AM EDT Learn about SEC filing dates

false 0001139685 0001139685 2026-08-18 2026-08-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2026 (August 18, 2026)

20/20 BIOLABS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-43128		57-2272107
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

15810 Gaither Road, Suite 235, Gaithersburg, MD		20877
(Address of principal executive offices)		(Zip Code)

240-453-6339

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01		AIDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 18, 2026, 20/20 Biolabs, Inc. (the “Company”) held an annual meeting of stockholders of the Company (the “Annual Meeting”) via live webcast. Holders of shares of the Company’s common stock at the close of business on June 22, 2026 were entitled to vote at the Annual Meeting. As of such date, there were 12,251,198 shares of common stock outstanding and entitled to vote. A total of 4,256,837 shares of common stock were represented in person or by valid proxies at the Annual Meeting, constituting a quorum.

Stockholders voted on five proposals at the Annual Meeting. The proposals are described in detail in the Company’s definitive proxy statement, dated June 23, 2026, the relevant portions of which are incorporated herein by reference. The final results for the votes cast for each proposal are set forth below, except for proposal 3 (Charter Amendment). The Company did not receive sufficient votes with respect to proposal 3 at the Annual Meeting. Accordingly, in accordance with proposal 5, the Company adjourned the Annual Meeting with respect to proposal 3 until September 16, 2026 at 10:00 a.m. Eastern Time. All stockholders may attend the adjourned meeting by visiting the same webinar portal used for the Annual Meeting at https://edge.media-server.com/mmc/go/AIDX2026AGM.

Proposal 1: The Company’s stockholders elected six directors to the Board of Directors of the Company to serve until the next annual meeting of stockholders of the Company or until such directors shall resign, be removed or otherwise leave office. The votes regarding this proposal were as follows:

		Votes For				Votes Withheld				Broker Non-Votes
Jonathan Cohen			2,733,310				89,806				1,433,721
John G. Compton, Ph.D.			2,668,095				155,021				1,433,721
Richard M. Cohen			2,647,263				175,853				1,433,721
Prasanth Reddy			2,653,831				169,285				1,433,721
John W. Rollins			2,652,712				170,404				1,433,721
Michael A. Ross, M.D.			2,667,412				155,704				1,433,721

Proposal 2: The Company’s stockholders ratified the appointment of dbbmckennon as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows:

Votes For		Votes Against		Abstentions
4,105,584		132,421		18,832

Proposal 4: The Company’s stockholders approved the Company’s 2026 Equity Incentive Plan. The votes regarding this proposal were as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
2,183,335		573,931		65,850		1,433,721

Proposal 5: The Company’s stockholders approved the adjournment of the Annual Meeting to a later date if necessary to solicit additional proxies if there are not sufficient votes to approve any of the foregoing proposals at the time of the Annual Meeting, or any adjournment or postponement thereof. The votes regarding this proposal were as follows:

Votes For		Votes Against		Abstentions
3,037,106		1,132,166		87,565

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 19, 2026	20/20 BIOLABS, INC.
	/s/ Jonathan Cohen
	Name:	Jonathan Cohen
	Title:	Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB